Referenser

  1. Svenskt njurregister. Årsrapport 2023: Svenskt njurregister; 2023

  2. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4s):S117-s314.

  3. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4s):S1-s276.

  4. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5s):S1-s127.

  5. Åkesson A, Lindström V, Nyman U, Jonsson M, Abrahamson M, Christensson A, et al. Shrunken pore syndrome and mortality: a cohort study of patients with measured GFR and known comorbidities. Scand J Clin Lab Invest. 2020;80(5):412-22.

  6. Farrington DK, Surapaneni A, Matsushita K, Seegmiller JC, Coresh J, Grams ME. Discrepancies between Cystatin C-Based and Creatinine-Based eGFR. Clin J Am Soc Nephrol. 2023;18(9):1143-52.

  7. Komenda P, Ferguson TW, Macdonald K, Rigatto C, Koolage C, Sood MM, et al. Cost-effectiveness of primary screening for CKD: a systematic review. Am J Kidney Dis. 2014;63(5):789-97.

  8. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int. 2012:pp. 1–138.

  9. Brown RS. Has the time come to include urine dipstick testing in screening asymptomatic young adults? Jama. 2011;306(7):764-5.

  10. Nationellt programområde för njur- och urinvägssjukdomar. Nationellt vårdprogram för kronisk njursjukdom: Sveriges regioner i samverkan; 2024 [Available from: https://kunskapsstyrningvard.se/kunskapsstyrningvard/kunskapsstod/publiceradekunskapsstod/njurochurinvagssjukdomar/kronisknjursjukdomvardprogram.82580.html

  11. Chiurchiu C, Remuzzi G, Ruggenenti P. Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses. J Am Soc Nephrol. 2005;16 Suppl 1:S58-63.

  12. Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol. 2010;6(6):319-30.

  13. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-46.

  14. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-84.

  15. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23):2219-29.

  16. Locatelli F, Bárány P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant. 2013;28(6):1346-59.

  17. Janusinfo. Smärtbehandling med gabapentin för vuxna, risk och nytta Stockholm: Region Stockholm; 2025 [Available from: https://janusinfo.se/behandling/expertgruppsutlatanden/smartaochreumatologiskasjukdomar/smartaochreumatologiskasjukdomar/smartbehandlingmedgabapentinforvuxnariskochnytta.5.701fee29194c8e005ebc14be.html

Föregående sida
För vidare läsning

Nästa sida
Tillbaka till kapitlets första sida